Sida continues to support IVI’s mission to accelerate vaccine research

NewsGuard 100/100 Score

The International Vaccine Institute (IVI), a Seoul, Korea-based international organization, announced today that the Swedish International Cooperation Agency (Sida) will continue to support IVI's mission to accelerate vaccine research and development for global health with a total contribution of SEK 50 million (approximately 5.24 million USD) over the next five years as part of a longstanding partnership between the Swedish government and IVI.

We're proud to have Sweden's long-term support and partnership. Unrestricted support from Sida enables IVI to implement strategic imperatives and pursue independent research and innovation. We're very grateful for the latitude to advance both our scientific portfolio and core activities.

Our partnership has made possible significant accomplishments in the past, including the development and delivery of the world's first affordable oral cholera vaccine. We're looking forward to further collaboration in achieving global goals."

Dr. Jerome Kim, Director General of IVI

Sweden was one of the first countries to sign the IVI Establishment Agreement in 1997 and started funding IVI in 2002 through Sida. Since IVI's first research collaboration with the University of Gothenburg and Swedish Biological Laboratories in 2000, Sweden has played an invaluable role in developing IVI's landmark oral cholera vaccine (OCV), Shanchol, and later, Euvichol and Euvichol Plus, vaccines developed through technology transfer from IVI and prequalified by the WHO. To date, over 42 million doses of these low-cost OCVs have been deployed worldwide.

"IVI's contribution to global health is invaluable considering both the technical support provided to low- and middle-income countries and the focus on diseases disproportionally affecting people living in poverty," said Dr Teresa Soop, Senior research advisor at Sida.

In addition to funding for IVI operations, Sida has previously granted additional project funding for IVI's priority disease areas: cholera, dengue, and typhoid. These funds have supported a range of epidemiology and vaccine programs, including generating evidence on disease burden across developing Asian and African countries; accelerating the development and introduction of affordable dengue, oral cholera, and typhoid vaccines across Asia and South America; and increasing the capacity of developing countries to implement immunization programs in Central Asia.

Sida's contribution to IVI extends beyond providing core funding and governance, to impacting operations and culture, particularly in the areas of sustainability and gender equality. With Sida's guidance, IVI initiated an Environmental Impact Assessment in 2018 which resulted in the formation of an internal Environmental Management System committee to oversee IVI's environmental impacts and champion sustainable development. IVI has also initiated efforts to further cultivate diversity and inclusion in personnel policies and leadership. These are two examples of how IVI benefits from and reciprocates partnership with its member states.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research expands understanding of vaccine-induced immune thrombocytopenia and thrombosis